

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show 8 Numbers](#)[Edit 8 Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
5686072.pn. or 5593676.pn. or 5494899.pn.	6

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L19

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Tuesday, August 27, 2002 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side**Hit Count Set Name**
result set*DB=USPT,DWPI; THES=ASSIGNEE; PLUR=YES; OP=OR*L19 5686072.pn. or 5593676.pn. or 5494899.pn.6 L19L18 L16 and @RLAD<20000101162 L18*DB=USPT,PGPB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=OR*L17 L16 and @RLAD<20000101210 L17L16 (((MSorEAE or sclerosis or autoimmun\$).ab. or (MS or EAE or sclerosis or autoimmun\$).clm.)) and ((B adj1 (cell or lymphocyte)) same (deplet\$ or lyse or inactivat\$ or eliminat\$))345 L16L15 L14 and @RLAD<20000101388 L15L14 (((MSor EAE or sclerosis or autoimmun\$).ab. or (MS or EAE or sclerosis or autoimmun\$).clm.)) and ((B adj1 (cell or lymphocyte)) same (deplet\$ or lyse or kill\$ or inactivat\$ or suppress or eliminat\$))710 L14L13 (((MSorEAE or sclerosis or autoimmun\$).ab. or (MS or EAE or sclerosis or autoimmun\$).clm.)) and ((B adj1 (cell or lymphocyte)) same (deplet\$ or lyse or kill\$ or inactivat\$ or suppress or eliminat\$))710 L13L12 (((MSor EAE or sclerosis or autoimmun\$).ab. or (MS or EAE or sclerosis or autoimmun\$).clm.)) and (B adj1 (cell or lymphocyte)) same (deplet\$ or lyse or kill\$ or inactivat\$ or suppress or eliminat\$)710 L12L11 ((MS or EAE or sclerosis or autoimmun\$).ab. or (MS or EAE or sclerosis or autoimmun\$).clm.) and (B adj1 (cell or lymphocyte)) same (deplet\$ or lyse or kill\$ or inactivat\$ or suppress or eliminat\$)743 L11L10 L5 and ((MS or EAE or sclerosis or autoimmun\$).ab. or (MS or EAE or sclerosis or autoimmun\$).clm.)743 L10L9 L5 same (MS or EAE or sclerosis or autoimmun\$)838 L9L8 L5 same (MS or EAE or sclerosis or autoimmun\$)563 L8L7 L6 and (MS or EAE or sclerosis)1677 L7L6 L5 and autoimmun\$1767 L6L5 (B adj1 (cell or lymphocyte)) same (deplet\$ or lyse or kill\$ or inactivat\$ or suppress or eliminat\$)3622 L5L4 Curd-John-g.in.0 L4L3 Nelson-M.-Bud.in.0 L3L2 Barbera-Guillem-emilo.in.0 L2L1 Hanna-nabil.in.31 L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 07:27:49 ON 27 AUG 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, PROMT' ENTERED AT 07:28:40 ON 27 AUG 2002

L1 3343 S CD22
L2 90220 S (MULTIPLE (1W) SCLEROSIS) OR EAE
L3 4886 S (B (1W) (CELL OR LYMPHOCYTE)) (5W) (DEPLET? OR ELIMINAT? OR
L
L4 62 S L3 AND ((MULTIPLE (1W) SCLEROSIS) OR EAE OR MS)
L5 39 DUP REM L4 (23 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 07:44:34 ON 27 AUG 2002

L6 0 S L4 AND L1
L7 0 S L1 AND L3

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, PROMT' ENTERED AT 07:51:39 ON 27 AUG 2002

L8 1 S L6
L9 51 S L7
L10 1 S L1 AND L4
L11 51 S L1 AND L3
L12 26 DUP REM L11 (25 DUPLICATES REMOVED)
L13 1 S L12 AND L2
L14 16 S L1 AND L2
L15 12 DUP REM L14 (4 DUPLICATES REMOVED)

L15 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2002:220424 CAPLUS
 DOCUMENT NUMBER: 136:246408
 TITLE: Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination.
 INVENTOR(S): Hanna, Nabil
 PATENT ASSIGNEE(S): Idec Pharmaceuticals, USA
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022212	A2	20020321	WO 2001-US29026	20010918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001091037	A5	20020326	AU 2001-91037	20010918
US 2002058029	A1	20020516	US 2001-954274	20010918
PRIORITY APPLN. INFO.:			US 2000-257147P	P 20001222
			US 2000-233067P	P 20000918
			US 2000-233607P	P 20000918
			WO 2001-US29026	W 20010918

L15 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:814347 CAPLUS

DOCUMENT NUMBER: 133:361915

TITLE: Treatment of autoimmune diseases with antagonists
which bind to B cell surface markers

INVENTOR(S): Curd, John G.; Kunkel, Lori A.; Grillo-Lopez, Antonio
J.

PATENT ASSIGNEE(S): Genentech, Inc., USA; Idec Pharmaceuticals, Inc.

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000067796	A1	20001116	WO 2000-US40018	20000504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1176981	A1	20020206	EP 2000-928991	20000504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011197	A	20020219	BR 2000-11197	20000504
NO 2001005417	A	20020107	NO 2001-5417	20011106
PRIORITY APPLN. INFO.:				
US 1999-133018P P 19990507				
US 1999-139621P P 19990617				
WO 2000-US40018 W 20000504				
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L5 ANSWER 13 OF 39

MEDLINE

DUPLICATE 3

ACCESSION NUMBER: 2000221272 MEDLINE

DOCUMENT NUMBER: 20221272 PubMed ID: 10756081

TITLE: B cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis: roles of B cell CD95, CD95L and Bcl-2 expression.

AUTHOR: White C A; Nguyen K B; Pender M P

CORPORATE SOURCE: Neuroimmunology Research Unit, Department of Medicine, The University of Queensland, Clinical Sciences Building,

Royal

Brisbane Hospital, Brisbane, Queensland, 4029, Australia.

SOURCE: JOURNAL OF AUTOIMMUNITY, (2000 May) 14 (3) 195-204.

Journal code: 8812164. ISSN: 0896-8411.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200006

ENTRY DATE: Entered STN: 20000706

Last Updated on STN: 20000706

Entered Medline: 20000626

AB The role and fate of B cells in the central nervous system (CNS) in experimental autoimmune encephalomyelitis (EAE) are unknown.

Using enzyme-linked immunospot assays we now show that B cells reactive to

myelin basic protein (MBP) accumulate in the CNS of Lewis rats with acute EAE induced by immunization with MBP and adjuvants. We also report that B cells are eliminated from the CNS by apoptosis during spontaneous recovery from this disease. Apoptotic B

cells

were identified by flow cytometry of inflammatory cells extracted from the

spinal cord and by histological sections of the spinal cord using light and electron microscopic immunocytochemistry. B cell apoptosis occurred preferentially in the CNS rather than in the peripheral lymphoid organs and was maximal just prior to the onset of spontaneous clinical recovery. Three colour flow cytometry indicated that B cells expressing CD95 (Fas) or CD95 ligand (CD95L) were highly vulnerable to apoptosis, whereas B cells expressing Bcl-2 were relatively protected from apoptosis. We propose that B cells are eliminated from the CNS by the interaction of CD95L and CD95 on the same B cell and that this contributes to the spontaneous resolution of CNS inflammation and clinical

recovery in acute EAE.

Copyright 2000 Academic Press.